Navigation Links
New U.S. Patent Issued To Dyadic International
Date:11/7/2013

JUPITER, Fla., November 7, 2013 /PRNewswire/ -- Dyadic International, Inc. (OTC Pink: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,551,751 B2 entitled, "BX11 Enzymes Having Xylosidase Activity" by the United States Patent and Trademark Office ("USPTO").

(Logo: http://photos.prnewswire.com/prnh/20110621/CL06708LOGO )

The invention relates to methods of developing and producing novel enzymes, more specifically for the development of a variety of fungal enzymes.  Also described in the patent is the encoding of nucleic acid molecules for such enzymes, compositions, recombinant, and genetically modified host cells, and methods of use. 

In addition, the patent also addresses methods to convert lignocellulosic biomass into fermentable sugars with enzymes that degrade the lignocellulosic material and novel combinations of enzymes, including those that provide a synergistic release of sugars from plant biomass.  Large amounts of carbohydrates in plant biomass provide a plentiful source of potential energy in the form of sugars that can be utilized to produce biofuels such as Cellulosic Ethanol and a variety of bio-based chemicals.  Additionally, the patent addresses methods to use the novel enzymes and compositions of such enzymes in a variety of other processes, including washing of clothing, detergent processes, biorefining, deinking and biobleaching of paper and pulp, and treatment of waste streams.

Dyadic's President and CEO, Mark Emalfarb, stated, "This latest patent builds upon our family of patents that address the conversion of lignocellulosic biomass into fermentable sugars for the production of renewable biofuels and bio-based chemicals using our proprietary C1 technology. This latest patent adds to our comprehensive IP portfolio further protecting our C1 protein expression system and the products derived therefrom, which continues to attract blue chip customers, partners, and collaborators."

This patent is the thirteenth U.S. patent issued to Dyadic adding to its portfolio of 41 international patents, 23 pending international and 11 pending U.S. patent applications which cover various features of Dyadic's proprietary technologies.

The newly issued patent is accessible on the USPTO's website at www.uspto.gov or on Dyadic's website at www.dyadic.com.

About Dyadic

Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries.

Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce.

Cautionary Statement for Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.


'/>"/>
SOURCE Dyadic International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Essential Medical Dismisses Patent Case against Masimo and Cercacor
2. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
3. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
4. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
5. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
6. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
7. Broad Patent Protection Granted for iBio Immunomodulator
8. Bio-AMD, Inc.; Patent Application for Cartridge Test Cap
9. Coloplast Wins Patent Infringement Verdict Against Generic Medical Devices, Inc.
10. ICU Medical, Inc. Plans to "Vigorously Seek to Collect Damages" in wake of Patent Infringement Victory Over RyMed Technologies
11. NeuroSigma Subsidiary Acquires Thin-Film Nitinol Fabrication Patent Portfolio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 26, 2016 ... care operating models within the health care industry is ... financial efficiency , Deloitte offers a suite of ... business issues impacting efficient cost optimization: labor resource analysis, ... These services facilitate better outcomes and better economics ...
(Date:6/24/2016)... Calif. , June 24, 2016  Global ... a biopharmaceutical company developing novel therapeutics for the ... needs, today announced the closing of its previously ... common stock, at the public offering price of ... the offering were offered by GBT. GBT estimates ...
(Date:6/24/2016)... DUBLIN , June 24, 2016 ... addition of the "Structural Electronics 2015-2025: Applications, ... In-Mold Electronics, Smart ... Integrated Photovoltaics Structural electronics involves ... as load-bearing, protective structures, replacing dumb structures such ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. ... accelerated orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, ... and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic ...
(Date:6/24/2016)... ... 24, 2016 , ... People across the U.S. are sharpening their pencils and ... essay contest in which patients and their families pay tribute to a genetic counselor ... National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , ...
(Date:6/24/2016)... Nevada (PRWEB) , ... June 24, 2016 , ... ... Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations ... in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):